United States research-based biopharmaceutical company AbbVie Inc. (NYSE: ABBV) announced on Friday its quarterly cash dividend.
The company has declared a quarterly cash dividend of USD1.55 per share. The dividend will be paid to shareholders of record as at 15 October 2024, on 15 November 2024.
AbbVie focuses on discovering and delivering transformational medicines and products in several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology and women's health, as well as through our Allergan Aesthetics portfolio.
USANA Health Sciences acquires controlling stake in Hiya Health for USD205m
Valneva and Serum Institute of India partner to expand chikungunya vaccine access in Asia
Lilly and EVA Pharma granted regulatory approval for locally manufactured insulin in Egypt
Abbott announces dividend increase and 53 years of growth
SK bioscience begins clinical trials for mRNA Japanese encephalitis vaccine